ZEVRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.52 USD | 0.00% |
|
0.00% | -30.99% |
| Sales 2024 * | 29.34M 40.06M | Sales 2025 * | 90.7M 124M | Capitalization | 189M 258M |
|---|---|---|---|---|---|
| Net income 2024 * | -69M -94.23M | Net income 2025 * | -20M -27.31M | EV / Sales 2024 * | 7.02 x |
| Net Debt 2024 * | 16.8M 22.94M | Net Debt 2025 * | 14.8M 20.21M | EV / Sales 2025 * | 2.25 x |
| P/E ratio 2024 * |
-2.85
x | P/E ratio 2025 * |
-8.75
x | Employees | 67 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zevra Therapeutics, Inc.
More recommendations
More press releases
| Current month | -22.07% | ||
| 1 month | -23.91% | ||
| 3 months | -24.35% | ||
| 6 months | +4.15% | ||
| Current year | -30.99% |
1 week
4.46
4.68
1 month
4.395.49
Current year
4.397.28
1 year
3.897.28
3 years
3.8915.70
5 years
1.9432.00
10 years
1.94418.40
| Managers | Title | Age | Since |
|---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 06-10-29 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 23-10-09 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 23-04-24 |
Tamara Favorito
CHM | Chairman | 65 | 21-08-17 |
| Director/Board Member | 56 | 23-04-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.44% | 4 M€ | -5.15% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.52 | 0.00% | 157,431 |
| 24-04-25 | 4.52 | -0.88% | 127,400 |
| 24-04-24 | 4.56 | -0.44% | 159,093 |
| 24-04-23 | 4.58 | +0.22% | 136,190 |
| 24-04-22 | 4.57 | +1.11% | 109,376 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.52
USD
Average target price
19
USD
Spread / Average Target
+320.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.99% | 189M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- ZVRA Stock
